PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 4 filers reported holding PROGENICS PHARMACEUTICALS IN in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $343,000 | -9.0% | 83,367 | +3.1% | 0.00% | 0.0% |
| Q4 2019 | $377,000 | -2.3% | 80,837 | +1.9% | 0.00% | 0.0% |
| Q3 2019 | $386,000 | -7.7% | 79,332 | +1.9% | 0.00% | 0.0% |
| Q2 2019 | $418,000 | -0.9% | 77,885 | -7.0% | 0.00% | 0.0% |
| Q1 2019 | $422,000 | +17.5% | 83,763 | +4.4% | 0.00% | 0.0% |
| Q4 2018 | $359,000 | -15.9% | 80,216 | -0.4% | 0.00% | 0.0% |
| Q3 2018 | $427,000 | -33.3% | 80,574 | +3.5% | 0.00% | -25.0% |
| Q2 2018 | $640,000 | +24.3% | 77,828 | +6.1% | 0.00% | 0.0% |
| Q1 2018 | $515,000 | +7.7% | 73,362 | +1.7% | 0.00% | +33.3% |
| Q4 2017 | $478,000 | +5.5% | 72,164 | -2.6% | 0.00% | 0.0% |
| Q3 2017 | $453,000 | -6.8% | 74,071 | +1.2% | 0.00% | -25.0% |
| Q2 2017 | $486,000 | -18.6% | 73,180 | -5.3% | 0.00% | -20.0% |
| Q1 2017 | $597,000 | – | 77,316 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARDSLEY ADVISORY PARTNERS LP | 1,255,000 | $5,823,000 | 1.12% |
| Phocas Financial Corp. | 1,146,292 | $5,319,000 | 0.54% |
| Worth Venture Partners, LLC | 138,357 | $641,000 | 0.36% |
| RICE HALL JAMES & ASSOCIATES, LLC | 2,293,179 | $10,640,000 | 0.34% |
| Monashee Investment Management LLC | 240,000 | $1,114,000 | 0.26% |
| BKS ADVISORS, LLC | 118,587 | $550,000 | 0.22% |
| PINNACLE ASSOCIATES LTD | 1,418,391 | $6,581,000 | 0.15% |
| FARALLON CAPITAL MANAGEMENT LLC | 4,200,820 | $19,492,000 | 0.15% |
| Fosun International Ltd | 472,580 | $2,174,000 | 0.14% |
| CARILLON TOWER ADVISERS, INC. | 3,948,024 | $18,318,000 | 0.13% |